1 week Ago By ABMN Staff
Analysts at StockNews.com began coverage on shares of InspireMD ( NYSE:NSPR – Get Free Report ) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.
A number of other brokerages have also commented on NSPR. Lake Street Capital initiated coverage on shares of InspireMD in a report on Wednesday, December 11th. They set a “buy” rating and a $5.
00 price objective on the stock. Piper Sandler reissued an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.
View Our Latest Report on NSPR InspireMD Trading Up 1.9 % InspireMD ( NYSE:NSPR – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.
16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04.
The firm had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million.
InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%.
During the same quarter in the previous year, the company posted ($0.15) EPS. As a group, analysts forecast that InspireMD will post -0.
79 EPS for the current fiscal year. Institutional Inflows and Outflows A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC acquired a new stake in shares of InspireMD, Inc.
( NYSE:NSPR – Free Report ) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.
74% of InspireMD as of its most recent filing with the Securities & Exchange Commission. 44.78% of the stock is currently owned by institutional investors.
InspireMD Company Profile ( Get Free Report ) InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. Read More Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.
com's FREE daily email newsletter ..
